REGENXBIO Inc. (RGNX) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 174.48M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $174.48M | (m) | (m) |
| 2026-03-31 | (m) | $87.82M | (m) | (m) |
| 2025-12-31 | (m) | $170.44M | (m) | (m) |
| 2025-09-30 | (m) | $161.32M | (m) | (m) |
| 2025-06-30 | (m) | $155.78M | (m) | (m) |
| 2025-03-31 | (m) | $156.72M | (m) | (m) |
| 2024-12-31 | (m) | $83.33M | $33.57M | (m) |
| 2024-09-30 | (m) | $84.33M | $38.49M | (m) |
| 2024-06-30 | (m) | $89.04M | $38.49M | (m) |
| 2024-03-31 | (m) | $86.73M | $37.38M | (m) |
| 2023-12-31 | (m) | $90.24M | $37.21M | (m) |
| 2023-09-30 | (m) | $99.37M | $38.76M | (m) |
| 2023-06-30 | (m) | $96.97M | $39.46M | (m) |
| 2023-03-31 | (m) | $109.64M | $42.94M | (m) |
| 2022-12-31 | (m) | $112.72M | $54.55M | (m) |
| 2022-09-30 | (m) | $480.03M | $64.82M | (m) |
| 2022-06-30 | (m) | $484.30M | $65.83M | (m) |
| 2022-03-31 | (m) | $473.68M | $62.70M | (m) |
| 2021-12-31 | (m) | $470.35M | $51.83M | (m) |
| 2021-09-30 | (m) | $93.14M | $39.03M | (m) |
| 2021-06-30 | (m) | $161.28M | $42.29M | (m) |
| 2021-03-31 | (m) | $155.81M | $37.16M | (m) |
| 2020-12-31 | (m) | $154.57M | $35.71M | (m) |
| 2020-09-30 | (m) | $144.89M | $29.25M | (m) |
| 2020-06-30 | (m) | $60.68M | $14.38M | (m) |
| 2020-03-31 | (m) | $51.99M | $11.62M | (m) |
| 2019-12-31 | (m) | $35.23M | $8.24M | (m) |
| 2019-09-30 | (m) | $64.24M | (m) | (m) |
| 2019-06-30 | (m) | $54.85M | (m) | (m) |
| 2019-03-31 | (m) | $87.00M | (m) | (m) |
| 2018-12-31 | (m) | $218.50M | (m) | (m) |
| 2018-09-30 | (m) | $179.77M | (m) | (m) |
| 2018-06-30 | (m) | $175.80M | (m) | (m) |
| 2018-03-31 | (m) | $142.33M | (m) | (m) |
| 2017-12-31 | (m) | $10.39M | (m) | (m) |
| 2017-09-30 | (m) | $10.05M | (m) | (m) |
| 2017-06-30 | (m) | $8.84M | (m) | (m) |
| 2017-03-31 | (m) | $4.65M | (m) | (m) |
| 2016-12-31 | (m) | $4.59M | (m) | (m) |
| 2016-09-30 | (m) | $7.34M | (m) | (m) |
| 2016-06-30 | (m) | $8.35M | (m) | (m) |
| 2016-03-31 | (m) | $7.34M | (m) | (m) |
| 2015-12-31 | (m) | $7.59M | (m) | (m) |
| 2015-09-30 | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | $3.64M | (m) | (m) |
| 2015-03-31 | (m) | $3.83M | (m) | (m) |
| 2014-12-31 | (m) | $6.12M | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $6.09M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |